Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added. The government funding status notice and Revision: v3.4.1 were removed.SummaryDifference0.2%

- Check21 days agoChange DetectedA government funding lapse notice was added, noting that the NIH Clinical Center is open and status updates can be found at opm.gov. The page was updated to revision v3.4.1, replacing the prior v3.4.0.SummaryDifference0.2%

- Check28 days agoChange DetectedAdded a Show glossary toggle and explicit Last Update Submitted that Met QC Criteria and Last Update Posted fields, and labeled No FEAR Act Data. Updated the page revision to v3.4.0 (from v3.3.4).SummaryDifference0.1%

- Check42 days agoChange DetectedRevision: v3.3.4 has been added. Revision: v3.3.3 has been removed.SummaryDifference0.0%

- Check64 days agoChange DetectedLocations section expanded to include numerous new sites across the United States and internationally, broadening the geographic coverage of the trial.SummaryDifference3%

- Check85 days agoChange DetectedA minor version label update is shown: Revision: v3.3.2 is now displayed, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.